Cellectar Biosciences has seen ups and downs in the last 18 months, including several changes in its top ranks. Now, as the cancer drug developer prepares to take its lead drug candidate into mid-stage clinical trials, CEO Jim Caruso seems more interested in talking about his company’s future than its past.
Madison, WI-based Cellectar (NASDAQ: CLRB) expects a Phase 2 trial for its lead drug candidate, known as CLR 131, will begin by March, and Caruso says data from the study could “really transform the company” from where it stands today.
“We’re laser-focused on CLR 131, without question,” Caruso says in an interview at Cellectar’s offices in Madison. The drug candidate, which has the potential to treat malignant tumors and certain forms of blood cancer, including multiple myeloma, is currently in a Phase 1 clinical trial. Read the full story here.